Last $1.74 USD
Change Today +0.05 / 2.96%
Volume 76.7K
PIP On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 4:15 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

pharmathene inc (PIP) Snapshot

Open
$1.70
Previous Close
$1.69
Day High
$1.74
Day Low
$1.70
52 Week High
09/10/14 - $2.59
52 Week Low
07/23/14 - $1.19
Market Cap
110.3M
Average Volume 10 Days
69.0K
EPS TTM
$-0.18
Shares Outstanding
63.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMATHENE INC (PIP)

pharmathene inc (PIP) Related Businessweek News

No Related Businessweek News Found

pharmathene inc (PIP) Details

PharmAthene, Inc., a biodefense company, develops and commercializes medical countermeasures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax; and recombinant butyrylcholinesterase bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds comprising nerve gases and pesticides. The company serves the United States Department of Defense, Chemical Biological Medical Systems, Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the National Institute of Health. It has collaboration with Bristol-Myers Squibb for developing Valortim; and strategic alliance with Nanotherapeutics, Inc. to develop biodefense programs. The company is headquartered in Annapolis, Maryland.

52 Employees
Last Reported Date: 03/11/14

pharmathene inc (PIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $456.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $318.0K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $326.4K
Senior Vice President of Policy & Government ...
Total Annual Compensation: $294.4K
Compensation as of Fiscal Year 2013.

pharmathene inc (PIP) Key Developments

PharmAthene, Inc. Fulfills Valortim(R) IDIQ Contract

PharmAthene, Inc. announced that it has fulfilled its obligations under a fixed price, indefinite delivery, indefinite quantity (IDIQ) contract, awarded in 2013 by the Biomedical Advanced Research and Development Authority (BARDA) for the Company's anthrax anti-toxin, Valortim(R). Under the IDIQ contract, PharmAthene was selected to provide a specified quantity of its Valortim(R) anthrax anti-toxin master cell bank for secure storage by the government as part of a risk mitigation strategy for anthrax medical countermeasures.

PharmAthene, Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

PharmAthene, Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s contract revenue was $962,451 against $3,488,142 for the same period of last year. Loss from operations was $3,996,030 against $3,199,182 for the same period of last year. Net loss before income taxes was $4,603,367 against $3,917,083 for the same period of last year. Net loss was $4,628,435 against $3,945,887 for the same period of last year. Basic and diluted net loss per share was $0.08 against $0.08 for the same period of last year. For the nine months, the company’s contract revenue was $8,363,909 against $14,258,680 for the same period of last year. Loss from operations was $7,567,767 against $5,771,645 for the same period of last year. Net loss before income taxes was $7,277,890 against $7,243,891 for the same period of last year. Net loss was $7,325,995 against $7,293,644 for the same period of last year. Basic and diluted net loss per share was $0.13 against $0.15 for the same period of last year.

PharmAthene, Inc. Wins a Contract of up to $28.1 Million to Develop Next Generation Thermostable Anthrax Vaccine

PharmAthene, Inc. announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next generation anthrax vaccine based on the Company's proprietary rPA anthrax vaccine technology platform. Various government agencies, including the Institute of Medicine, have acknowledged the need to develop and stockpile next generation anthrax vaccines employing modern vaccine technology, which offer the potential for improved safety, convenience, cost-effectiveness, and more rapid immunity.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIP:US $1.74 USD +0.05

PIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $72.27 USD +1.54
Bayer AG €113.32 EUR +2.17
Protalix BioTherapeutics Inc 797.30 -17.50
View Industry Companies
 

Industry Analysis

PIP

Industry Average

Valuation PIP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.3x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMATHENE INC, please visit www.pharmathene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.